PharmAust Limited (PAA.AX)
AUD 0.23
(6.98%)
AUD 0.23
(6.98%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -9.45 Million AUD | -186.76% |
| 2023 | -3.29 Million AUD | -35.41% |
| 2022 | -1.3 Million AUD | 2.3% |
| 2021 | -960.05 Thousand AUD | -31.38% |
| 2020 | -968.85 Thousand AUD | -40.6% |
| 2019 | -1.33 Million AUD | 44.07% |
| 2018 | -2.37 Million AUD | -103.16% |
| 2017 | -1.16 Million AUD | 31.9% |
| 2016 | -3.77 Million AUD | 7.91% |
| 2015 | -1.84 Million AUD | -42.39% |
| 2014 | -1.26 Million AUD | -138.75% |
| 2013 | -556.86 Thousand AUD | 86.62% |
| 2012 | -4.16 Million AUD | -470.25% |
| 2011 | -5.72 Million AUD | -169.24% |
| 2010 | -271.08 Thousand AUD | -1305.34% |
| 2009 | 22.49 Thousand AUD | 100.49% |
| 2008 | -3.78 Million AUD | 16.76% |
| 2007 | -5.48 Million AUD | -160.47% |
| 2006 | -2.25 Million AUD | -9.42% |
| 2005 | -3.11 Million AUD | -88.59% |
| 2004 | -1.02 Million AUD | 20.46% |
| 2003 | -1.28 Million AUD | 57.87% |
| 2002 | -3.04 Million AUD | -65.17% |
| 2001 | -1.84 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | -101.97% |
| 2024 Q2 | -1.52 Million AUD | 0.0% |
| 2024 Q4 | -4.19 Million AUD | 0.0% |
| 2023 Q4 | -2.48 Million AUD | 0.0% |
| 2023 FY | - AUD | -35.41% |
| 2023 Q2 | -811.1 Thousand AUD | 0.0% |
| 2022 FY | - AUD | 2.3% |
| 2022 Q4 | -1.37 Million AUD | 0.0% |
| 2022 Q2 | -1.05 Million AUD | 0.0% |
| 2021 FY | - AUD | -31.38% |
| 2021 Q2 | -1.31 Million AUD | 0.0% |
| 2021 Q4 | -1.18 Million AUD | 0.0% |
| 2020 Q2 | -1.05 Million AUD | 0.0% |
| 2020 FY | - AUD | -40.6% |
| 2020 Q4 | -838.88 Thousand AUD | 0.0% |
| 2019 FY | - AUD | 44.07% |
| 2019 Q2 | 14.28 Thousand AUD | 0.0% |
| 2019 Q4 | -1.36 Million AUD | 0.0% |
| 2018 Q2 | -1.43 Million AUD | 0.0% |
| 2018 FY | - AUD | -103.16% |
| 2018 Q4 | -978.81 Thousand AUD | 0.0% |
| 2017 Q4 | -862.52 Thousand AUD | 0.0% |
| 2017 Q2 | -324.55 Thousand AUD | 0.0% |
| 2017 FY | - AUD | 31.9% |
| 2016 Q4 | -844.45 Thousand AUD | 0.0% |
| 2016 Q2 | -898.81 Thousand AUD | 0.0% |
| 2016 FY | - AUD | 7.91% |
| 2015 FY | - AUD | -42.39% |
| 2015 Q4 | -853.84 Thousand AUD | 0.0% |
| 2015 Q2 | -1.03 Million AUD | 0.0% |
| 2014 Q2 | -612.55 Thousand AUD | -466.41% |
| 2014 Q1 | -108.14 Thousand AUD | 0.0% |
| 2014 FY | - AUD | -138.75% |
| 2014 Q4 | -716.96 Thousand AUD | 0.0% |
| 2013 Q2 | -269.5 Thousand AUD | 74.1% |
| 2013 Q3 | -108.14 Thousand AUD | 59.87% |
| 2013 Q1 | -1.04 Million AUD | 0.0% |
| 2013 Q4 | -108.14 Thousand AUD | 0.0% |
| 2013 FY | - AUD | 86.62% |
| 2012 FY | - AUD | -470.25% |
| 2012 Q4 | -1.04 Million AUD | 0.0% |
| 2012 Q3 | -1.04 Million AUD | 0.0% |
| 2012 Q2 | -1.04 Million AUD | 27.34% |
| 2012 Q1 | -1.43 Million AUD | 0.0% |
| 2011 FY | - AUD | -169.24% |
| 2011 Q4 | -1.43 Million AUD | 0.0% |
| 2011 Q1 | -67.77 Thousand AUD | 0.0% |
| 2011 Q2 | -1.43 Million AUD | -2013.14% |
| 2011 Q3 | -1.43 Million AUD | 0.0% |
| 2010 Q2 | -67.77 Thousand AUD | -1305.34% |
| 2010 FY | - AUD | -1305.34% |
| 2010 Q1 | 5622.50 AUD | 0.0% |
| 2010 Q4 | -67.77 Thousand AUD | 0.0% |
| 2010 Q3 | -67.77 Thousand AUD | 0.0% |
| 2009 FY | - AUD | 100.49% |
| 2009 Q1 | -1.33 Million AUD | 0.0% |
| 2009 Q2 | 5622.50 AUD | 100.42% |
| 2009 Q3 | 5622.50 AUD | 0.0% |
| 2009 Q4 | 5622.50 AUD | 0.0% |
| 2008 Q2 | -1.33 Million AUD | -81.0% |
| 2008 Q3 | -1.33 Million AUD | 0.0% |
| 2008 Q4 | -1.33 Million AUD | 0.0% |
| 2008 FY | - AUD | 16.76% |
| 2008 Q1 | -737.91 Thousand AUD | 0.0% |
| 2007 Q1 | -563.94 Thousand AUD | 0.0% |
| 2007 Q4 | -737.91 Thousand AUD | 0.0% |
| 2007 Q3 | -737.91 Thousand AUD | 0.0% |
| 2007 FY | - AUD | -160.47% |
| 2007 Q2 | -737.91 Thousand AUD | -30.85% |
| 2006 FY | - AUD | -9.42% |
| 2006 Q2 | -563.94 Thousand AUD | 65.82% |
| 2006 Q3 | -563.94 Thousand AUD | 0.0% |
| 2006 Q4 | -563.94 Thousand AUD | 0.0% |
| 2006 Q1 | -1.64 Million AUD | 0.0% |
| 2005 Q3 | -1.64 Million AUD | 0.0% |
| 2005 Q2 | -1.64 Million AUD | -187.75% |
| 2005 Q1 | -573.38 Thousand AUD | 0.0% |
| 2005 Q4 | -1.64 Million AUD | 0.0% |
| 2005 FY | - AUD | -88.59% |
| 2004 Q3 | -573.38 Thousand AUD | 0.0% |
| 2004 Q1 | -800.49 Thousand AUD | 0.0% |
| 2004 FY | - AUD | 20.46% |
| 2004 Q4 | -573.38 Thousand AUD | 0.0% |
| 2004 Q2 | -573.38 Thousand AUD | 28.37% |
| 2003 Q1 | -1.64 Million AUD | 0.0% |
| 2003 FY | - AUD | 57.87% |
| 2003 Q2 | -800.49 Thousand AUD | 51.43% |
| 2003 Q4 | -800.49 Thousand AUD | 0.0% |
| 2003 Q3 | -800.49 Thousand AUD | 0.0% |
| 2002 Q3 | -1.64 Million AUD | 0.0% |
| 2002 FY | - AUD | -65.17% |
| 2002 Q4 | -1.64 Million AUD | 0.0% |
| 2002 Q2 | -1.64 Million AUD | -67.4% |
| 2002 Q1 | -984.5 Thousand AUD | 0.0% |
| 2001 Q3 | -984.5 Thousand AUD | 0.0% |
| 2001 Q4 | -984.5 Thousand AUD | 0.0% |
| 2001 Q2 | -984.5 Thousand AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | -78.243% |
| Acrux Limited | -7.93 Million AUD | -19.174% |
| Actinogen Medical Limited | -12.92 Million AUD | 26.851% |
| AnteoTech Limited | -11.57 Million AUD | 18.315% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -398.09% |
| Arovella Therapeutics Limited | -8.83 Million AUD | -7.003% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -548.86% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 51.707% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -107.293% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -191.494% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -217.706% |
| Biome Australia Limited | -1.57 Million AUD | -498.873% |
| Biotron Limited | -5.04 Million AUD | -87.532% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 32.097% |
| BTC Health Limited | 1.05 Million AUD | 995.654% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 16.355% |
| CSL Limited | 4.73 Billion AUD | 100.2% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 78.83% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 118.224% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 5.01% |
| Dimerix Limited | -24.95 Million AUD | 62.13% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 191.097% |
| Hexima Limited | -995.54 Thousand AUD | -849.403% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -235.391% |
| Immuron Limited | -6.19 Million AUD | -52.635% |
| Immutep Limited | -42.87 Million AUD | 77.955% |
| Imugene Limited | -147.97 Million AUD | 93.613% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -1211.935% |
| Memphasys Limited | -3.3 Million AUD | -185.747% |
| Nanollose Limited | -1.14 Million AUD | -723.391% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 104.743% |
| Noxopharm Limited | -5.94 Million AUD | -58.973% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -426.181% |
| Nyrada Inc. | -4.59 Million AUD | -105.642% |
| Orthocell Limited | -11.68 Million AUD | 19.086% |
| Patrys Limited | -3.49 Million AUD | -170.656% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 85.355% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -19.834% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -31.535% |
| PYC Therapeutics Limited | -38.11 Million AUD | 75.204% |
| Race Oncology Limited | -14.2 Million AUD | 33.454% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 79.17% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 55.738% |
| Starpharma Holdings Limited | -12.57 Million AUD | 24.849% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 141.155% |
| Tissue Repair Ltd | -5.77 Million AUD | -63.666% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 74.063% |